
Arkansas Medical Cannabis Sales Surge to $291M in 2025
State's MMJ market posts 5.5% growth over 2024, setting new revenue record
Arkansas medical marijuana dispensaries rang up $291 million in sales during 2025, marking a new high for the state's five-year-old program and extending a growth trajectory that shows no signs of slowing.
The figure represents a $15 million increase over 2024's $276 million total and surpasses the previous record of $283 million set in 2023. The 5.5% year-over-year growth comes as Arkansas continues operating one of the more restrictive medical cannabis programs in the South—yet one that's proven remarkably resilient.
Arkansas voters approved medical marijuana in 2016, with the first dispensaries opening in 2019. The state currently has 38 licensed dispensaries serving roughly 90,000 registered patients across qualifying conditions including cancer, PTSD, and chronic pain.
Market Dynamics
The steady climb in sales suggests Arkansas patients are either consuming more cannabis or that the program continues adding new cardholders—or both. Average monthly sales in 2025 topped $24 million, compared to $23 million per month in 2024.
But the state's medical program operates under tight constraints. Arkansas caps cultivation licenses at eight and dispensary licenses at 40 (with two still unlicensed). The limited license structure has created a stable market for existing operators, though critics argue it keeps prices artificially high and limits patient access.
Retail prices in Arkansas typically run $10-15 per gram for flower, with concentrates and edibles commanding premium prices. The lack of home cultivation rights means patients must purchase all their cannabis from licensed dispensaries, driving consistent retail traffic.
The Adult-Use Question
Arkansas voters narrowly rejected adult-use legalization in November 2022, with the measure failing 56% to 44%. That defeat came despite polling showing initial majority support, after opponents—including some existing medical operators—mounted an effective late campaign.
The loss means Arkansas remains medical-only while neighboring Missouri has launched adult-use sales. Some industry observers believe Missouri's market is siphoning potential Arkansas patients who can more easily access cannabis across state lines. Yet the 2025 sales figures suggest Arkansas' medical program remains robust.
Another adult-use ballot initiative could materialize in 2026, though no organized campaign has emerged yet. The 2025 legislative session saw multiple cannabis reform bills introduced, including measures to expand qualifying conditions and reduce licensing fees, though none advanced significantly.
What's Next
The Arkansas Medical Marijuana Commission continues processing applications for the two remaining dispensary licenses, which could add incremental sales once operational. The state also recently streamlined its patient registration process, potentially lowering barriers to entry for new cardholders.
Industry analysts will be watching whether Arkansas can maintain its growth rate in 2026. The state's medical program has now posted positive year-over-year growth in four of its five full years of operation—an impressive track record for a limited-license market.
For existing operators, the $291 million figure represents stability in an industry where many state markets have seen sales flatten or decline as initial excitement wanes. Arkansas appears to have found a sustainable equilibrium, even without the adult-use expansion that's transformed markets elsewhere.
This article is based on original reporting by mjbizdaily.com.
Original Source
This article is based on reporting from MJBizDaily.
Read the original articleOriginal title: "Arkansas medical cannabis sales hit record $291 million in 2025"
Related Topics
Related Stories
Fluent Shutters New York Cultivation Facility, 37 Jobs Cut
Fluent Cannabis is closing Etain's Chestertown cultivation facility in New York, cutting 37 jobs as it prepares to merge with Vireo Health amid ongoing market consolidation and oversupply challenges.
Medical Cannabis Operators Rush to Register with DEA Post-Rescheduling
Medical cannabis operators are rushing to register with the DEA following marijuana rescheduling, hoping to secure 280E tax relief despite unclear federal guidance on whether registration will be mandatory.
New Study Links Medical Cannabis Access to Lower Opioid Use
New research shows medical cannabis patients reduced opioid use when programs were accessible and affordable, challenging gateway drug narratives as overdose deaths continue.
More from Alex Morgan
View all articlesFluent Shutters New York Cultivation Facility, 37 Jobs Cut
New Study Links Medical Cannabis Access to Lower Opioid Use
Medical Cannabis Operators Rush to Register with DEA Post-Rescheduling

